PMV Pharmaceuticals (PMVP) Competitors $1.00 -0.04 (-3.85%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. CRVS, YMAB, NVCT, OCGN, LFCR, GOSS, CRGX, PLX, HUMA, and ZYBTShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Ocugen (OCGN), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), CARGO Therapeutics (CRGX), Protalix BioTherapeutics (PLX), Humacyte (HUMA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Corvus Pharmaceuticals Y-mAbs Therapeutics Nuvectis Pharma Ocugen Lifecore Biomedical Gossamer Bio CARGO Therapeutics Protalix BioTherapeutics Humacyte Zhengye Biotechnology PMV Pharmaceuticals (NASDAQ:PMVP) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has better earnings and valuation, PMVP or CRVS? Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$68.96M-$1.14-0.88Corvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.33 Does the MarketBeat Community favor PMVP or CRVS? Corvus Pharmaceuticals received 269 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. However, 63.16% of users gave PMV Pharmaceuticals an outperform vote while only 62.08% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPMV PharmaceuticalsOutperform Votes2463.16% Underperform Votes1436.84% Corvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Do insiders & institutionals have more ownership in PMVP or CRVS? 90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, PMVP or CRVS? PMV Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Is PMVP or CRVS more profitable? PMV Pharmaceuticals' return on equity of -24.20% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -24.20% -21.67% Corvus Pharmaceuticals N/A -70.71%-45.90% Do analysts rate PMVP or CRVS? PMV Pharmaceuticals currently has a consensus price target of $5.67, suggesting a potential upside of 466.67%. Corvus Pharmaceuticals has a consensus price target of $15.67, suggesting a potential upside of 385.04%. Given PMV Pharmaceuticals' higher probable upside, equities research analysts clearly believe PMV Pharmaceuticals is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer PMVP or CRVS? In the previous week, PMV Pharmaceuticals' average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 1.22 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment PMV Pharmaceuticals Very Positive Corvus Pharmaceuticals Positive SummaryPMV Pharmaceuticals beats Corvus Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Remove Ads Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.93M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.006.7221.6917.68Price / SalesN/A223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book0.235.776.373.94Net Income-$68.96M$142.23M$3.20B$247.45M7 Day Performance5.91%2.72%1.67%0.48%1 Month Performance-20.63%-14.04%-9.49%-7.08%1 Year Performance-37.50%-12.31%9.59%-0.35% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals3.0449 of 5 stars$1.00-3.8%$5.67+466.7%-36.4%$51.93MN/A-1.0050CRVSCorvus Pharmaceuticals3.0382 of 5 stars$2.91+2.1%$15.67+438.4%+120.4%$198.28MN/A-3.1330YMABY-mAbs Therapeutics3.703 of 5 stars$4.28-5.7%$18.30+327.6%-64.1%$193.53M$87.69M-7.93150Short Interest ↓NVCTNuvectis Pharma2.7733 of 5 stars$8.24-0.1%$15.67+90.1%+48.7%$192.75MN/A-7.108Gap DownOCGNOcugen1.0525 of 5 stars$0.65-2.0%$6.33+876.2%-56.1%$189.46M$4.06M-3.6080Gap DownLFCRLifecore Biomedical1.828 of 5 stars$5.10-3.6%$8.00+56.9%+0.0%$188.83M$130.86M-9.11690High Trading VolumeGOSSGossamer Bio3.7757 of 5 stars$0.82+2.6%$7.75+844.4%-3.3%$186.46M$114.70M-2.56180Short Interest ↑CRGXCARGO Therapeutics2.8124 of 5 stars$4.03+0.2%$15.00+272.2%-77.1%$185.59MN/A-0.95116High Trading VolumePLXProtalix BioTherapeutics2.4258 of 5 stars$2.34-2.1%$15.00+541.0%+127.8%$182.60M$53.40M-18.00200HUMAHumacyte2.5627 of 5 stars$1.26-6.7%$13.71+988.4%-46.3%$182.50M$1.57M-0.94150News CoveragePositive NewsGap UpZYBTZhengye BiotechnologyN/A$3.85-10.3%N/AN/A$181.59M$189.75M0.00278Gap Down Remove Ads Related Companies and Tools Related Companies Corvus Pharmaceuticals Alternatives Y-mAbs Therapeutics Alternatives Nuvectis Pharma Alternatives Ocugen Alternatives Lifecore Biomedical Alternatives Gossamer Bio Alternatives CARGO Therapeutics Alternatives Protalix BioTherapeutics Alternatives Humacyte Alternatives Zhengye Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMVP Stock Free PMVP Stock Alerts